Linked Life Data

20809462

Source:http://linkedlifedata.com/resource/pubmed/id/20809462

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2010-9-2
pubmed:abstractText
In patients with chronic HBV infection, immunosuppressive therapy leads to the loss of immune control of replication and excessive increase of HBV viremia. Reactivation of HBV is usually characterized by ALT activity elevation but it may also cause acute liver failure. In patients with a past history of HBV infection (anti-HBc positive), the virus persists in liver cells and may lead to HBV recurrence with identical manifestation. Reactivation and recurrence of hepatitis B may be induced not only by immunosuppressive therapy, but also by anti-CD20 or anti-TNFa treatment. In inactive HBsAg carriers, HBV recurrence and reactivation may be prevented by prophylactic antiviral therapy with lamivudine or other synthetic antivirals (tenofovir, entecavir). Patients who underwent HBV infection in the past should be closely monitored and the treatment should be started when viremia increases. In chronic HCV infection, viremia also increases due to immunosuppression, progression of liver fibrosis is accelerated, but fulminant liver failure is rare. In HCV infected patients, preemptive antiviral treatment cannot be used. In immunocompromised patients, therapy with peginterferon alpha should be indicated individually. Kidney transplant candidates should undergo antiviral treatment before kidney transplantation, during the hemodialysis period.
pubmed:language
cze
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1211-264X
pubmed:author
pubmed:issnType
Print
pubmed:volume
16
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
120-3
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
[Viral hepatitis in immunosuppressed patients].
pubmed:affiliation
Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. jan.sperl@medicon.cz
pubmed:publicationType
Journal Article, English Abstract, Review